News Releases
- October 11, 2022Annovis Bio Announces Publication of Phase 2a Clinical Data in The Journal of Prevention of Alzheimer's Disease
- October 6, 2022Annovis Bio Announces FDA Authorization to Proceed with Phase 2/3 Trial for Buntanetap in Alzheimer's Disease
- September 29, 2022Annovis Bio to Present at the 2022 Ladenburg Thalmann Healthcare Conference
- September 13, 2022Annovis Bio Announces Publication of Patents Covering the Treatment of Amyloid Lateral Sclerosis, Huntington's Disease and Prion Diseases
- September 8, 2022Annovis Bio's CEO Maria Maccecchini Issues Letter to Stockholders
- August 29, 2022Annovis Bio Appoints Henry Hagopian III as Chief Financial Officer
- August 24, 2022Annovis Bio Announces First Patient Dosed in Phase 3 Trial in Patients with Early Parkinson's Disease
- August 8, 2022Annovis Bio Announces Second Quarter 2022 Results and Provides Corporate Update
- August 1, 2022Annovis Bio to Participate on Alzheimer's Association International Conference Panel
- July 14, 2022Annovis Bio to Present at the Alzheimer's Association International Conference
- ,
Media Coverage
Events & Presentations
-
Annovis R&D Day Webcast View Webcast
-
Annovis Corporate Presentation - February 2024
-
AD-PD Conference - March 2022
Filings
Filings
Description
Date Filed
Available Formats
E-mail Alerts
Back to Top